Navigation Links
Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
Date:3/26/2009

tration (the FDA) will take enforcement action against us or one or more of our marketed drugs which do not have FDA-approved marketing applications; patient, physician and third-party payor acceptance of our products as safe and effective therapeutic products; our heavy dependence on the commercial success of a relatively small number of currently marketed products; our ability to maintain regulatory approvals to market and sell our products that do have FDA approved marketing applications; our ability to enter into additional strategic licensing, collaboration or co-promotion transactions on favorable terms, if at all; our ability to maintain compliance with NASDAQ listing requirements; adverse side effects experienced by patients taking our products; difficulties relating to clinical trials, including difficulties or delays in the completion of patient enrollment, data collection or data analysis; the results of preclinical studies and clinical trials with respect to our products under development and whether such results will be indicative of results obtained in later clinical trials; our ability to satisfy FDA and other regulatory requirements; our ability to obtain, maintain and enforce patent and other intellectual property protection for our products and product candidates; and the other factors described in our Current Report on Form 8K, as amended, filed with the Securities and Exchange Commission (the SEC) on November 5, 2008, in the section titled "Risk Factors of the Registrant" as set forth in Exhibit 99.3, and other filings that we make with the SEC. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

In addition, the statements in this press release reflect our expectations and beliefs as of the date of this rele
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
2. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
3. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
4. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Tuesday, March 24, 2009
5. Cell Therapeutics Announces Filing of Form 10-K
6. Horizon Therapeutics Selected to Present at InsideVentures Debut Investor Conference March 25-26, Santa Barbara, California
7. Oxygen Biotherapeutics, Inc. Expands Board of Directors
8. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
9. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
10. Nile Therapeutics Announces Information in Compliance With NASDAQ Marketplace Rule 4350 and Reiterates 2009 Objectives
11. Medarex to Present at the Needham Cancer Therapeutics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Medical, Inc. (Nasdaq: AEMD ), the pioneer in ... announced that it will host its First Quarter Fiscal ... 13, 2015 at 4:30 p.m. Eastern Time. ... fiscal 2016 first quarter results.  A recorded version of ... the call at the Investor Relations portion of the ...
(Date:8/3/2015)... 3, 2015 According to a ... Cell Culture: Asia to Witness ... the global 3D cell culture market was valued at US$ 586.1 ... a CAGR of 29.1% to account for US$ 2,717.6 ... TOC:  http://www.persistencemarketresearch.com/market-research/3d-cell-cultures-market.asp 3D cell culture refers ...
(Date:7/31/2015)... 2015 In today,s fast changing healthcare ... drive positive health outcomes, improve profitability and enhance ... care in their communities. At ThoughtSpot 2015, ... AmerisourceBergen announced a new set of innovative capabilities ... and help independent pharmacies endure the industry,s most ...
(Date:7/31/2015)... ... 2015 , ... R-Biopharm is proud to announce the RIDASCREEN® ... foods, has been accepted by AOAC International as Official First Action method. The ... Products by R5 Competitive ELISA,” based on a specific monoclonal antibody to potentially ...
Breaking Biology Technology:Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2
... EMERYVILLE, Calif., Aug. 3 Bionovo, Inc. (Nasdaq: ... second quarter of fiscal year 2009 ended June 30, 2009 on Monday, ... cast to review the financial results on Monday, August 10, 2009 at ... the call by dialing (800) 860-2442 or (412) 858-4600, or can listen ...
... , , , ... Inc. (Nasdaq: SNMX ), a leading company focused on ... the food, beverage, and ingredient supply industries, and Firmenich SA, the ... have entered into a collaborative research, development, commercialization and license agreement ...
... , , EMERYVILLE, ... NBY ) today announced that Roy J. Wu ... business development. Wu brings to NovaBay more than 30 ... with increasingly responsible management positions in global business development, ...
Cached Biology Technology:Bionovo, Inc. to Announce Second Quarter Fiscal Year 2009 Financial Results on Monday, August 10, 2009 2SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY, DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS 2SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY, DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS 3SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY, DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS 4SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY, DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS 5NovaBay(R) Pharmaceuticals Names Roy J. Wu as Senior Vice President for Business Development 2NovaBay(R) Pharmaceuticals Names Roy J. Wu as Senior Vice President for Business Development 3
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. ... a biometric authentication company focused on the growing ... smart wallet, announces that it has filed provisional ... and Method. This invention highlights ... only authorizes an account, but also the user ...
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION ... new convenient and secure method to make payments.  ... payment methods, introduced with its groundbreaking voice-direct payment ...
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, ... ), the leading developer of human interface ... authentication technology, the industry,s first fully hardware ... innovative Match-in-Sensor secure authentication technology is literally ... pattern storage and biometric matching within the ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... a common feature of prion disease-affected human, mouse, and ... Neena Singh and colleagues at Case Western Reserve University ... findings, published March 13 in the open-access journal ... of neurotoxicity in prion disorders, and novel avenues for ...
... Kansas State,University, with collaboration from Epitopix LLC, have ... E. coli O157 in beef cattle. ... the post-harvest food safety,aspect, whether it,s E. ... College of Veterinary Medicine. Thomson is the Jones,Professor ...
... German . The Aarhus University ... between the many conference participants and according to ... Kyoto was very successful in doing so: "I am ... will undoubtedly contribute significantly to the future climate debate ...
Cached Biology News:Iron is involved in prion disease-associated neuronal demise 2K-State researchers help Epitopix license the United States' first E. coli O157 vaccine for cattle 2Seven recommendations from Aarhus to COP15 2Seven recommendations from Aarhus to COP15 3
... Pulser Xcell microbial system, 100 to ... for electroporation of bacterial and fungal ... unit, PC module for exponential decay ... cuvettes (5 each of 0.1 and ...
... yellow solution. In PBS ... and other proprietary stabilizers; ... formulated to stabilize activity ... conjugates at high conjugate ...
... Xcell eukaryotic system, 100 to ... used for electroporation of mammalian ... main unit, CE module for ... square-wave pulses, ShockPod shocking chamber, ...
... on Macintosh operating systems to predict ... sequence up to 3,200 bases, which ... and GC clamps for mutation detection ... constant denaturing gel electrophoresis (CDGE), and ...
Biology Products: